These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32434476)

  • 1. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
    Liu Z; Deng M; Wu L; Zhang S
    Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and Prognostic Significance of Keap1 mRNA Expression for Lung Cancer Based on Microarray and Clinical Information from Oncomine Database.
    Liu GY; Zhang W; Chen XC; Wu WJ; Wan SQ
    Curr Med Sci; 2021 Jun; 41(3):597-609. PubMed ID: 34169426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma.
    Xu Y; She Y; Li Y; Li H; Jia Z; Jiang G; Liang L; Duan L
    Biomed Pharmacother; 2020 May; 125():109859. PubMed ID: 32036209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.
    Sánchez-Ortega M; Garrido A; Cirauqui C; Sanz-Gonzalez L; Hernández MC; González-García A; Obregon K; Ferrer I; Paz-Ares L; Carrera AC
    Redox Biol; 2024 Sep; 75():103305. PubMed ID: 39137583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
    Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
    Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
    Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative analysis indicates SLC7A11 expression regulate the prognostic value of KEAP1-NFE2L2-CUL3 mutations in human uterine corpus endometrial carcinoma.
    Namani A; Veeraiyan D; Patra T
    Free Radic Biol Med; 2024 Sep; 222():223-228. PubMed ID: 38876457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of downregulated ADARB1 in lung squamous cell carcinoma.
    Wang X; Ren X; Liu W; Chen X; Wei J; Gong Z; Yan Y; Xu Z
    Mol Med Rep; 2020 Mar; 21(3):1517-1526. PubMed ID: 32016472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 12. Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer.
    Martinez VD; Vucic EA; Thu KL; Pikor LA; Lam S; Lam WL
    Head Neck; 2015 May; 37(5):727-34. PubMed ID: 24596130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
    Paik PK; Fan PD; Qeriqi B; Namakydoust A; Daly B; Ahn L; Kim R; Plodkowski A; Ni A; Chang J; Fanaroff R; Ladanyi M; de Stanchina E; Rudin CM
    J Thorac Oncol; 2023 Apr; 18(4):516-526. PubMed ID: 36240971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
    Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
    Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
    Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns.
    Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S
    Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
    Kim A; Lim SM; Kim JH; Seo JS
    Front Immunol; 2021; 12():598671. PubMed ID: 33717076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple mutations of lung squamous cell carcinoma shared common mechanisms.
    Li Q; Hou J; Hu Z; Gu B; Shi Y
    Oncotarget; 2016 Nov; 7(48):79629-79636. PubMed ID: 27835590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
    Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
    Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
    Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
    Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.